Esophageal cancer patients who suffer loss of muscle mass (sarcopenia) during neoadjuvant therapy (chemotherapy prior to surgery) survive, on average, 32 months less than patients with no sarcopenia, new research concludes.
Esophageal cancer patients who suffer loss of muscle mass (sarcopenia) during neoadjuvant therapy (chemotherapy prior to surgery) survive, on average, 32 months less than patients with no sarcopenia, new research concludes.